Index

Note: Page numbers in italics refer to Figures; those in bold to Tables.

acquired immune deficiency syndrome (AIDS), 364, 365, 368
see also human immunodeficiency virus (HIV) infection
diarrhoea, 381
acute kidney injury (AKI), 233
metabolic changes
hypercatabolism, factors, 234
lipid and carbohydrate metabolism, 234–5
protein metabolism, 234
vitamins and minerals, 235
nutritional requirements, 235, 235
nutritional support, 235–6
nutritional treatment, 234
acute liver failure (ALF), 195
carbohydrate metabolism, 197–8
energy requirements, 196
fat metabolism, 198
nutritional therapy, 201, 201, 201, 202
protein and amino acid metabolism, 199
acute lymphocytic leukaemia (ALL), 255
acute myeloid leukaemia (AML), 254–5
acute-phase proteins, biological functions, 280, 280
adenosine 5′-triphosphate (ATP), cancer patients, 418
adolescents, 444–6
adults, nutrition screening tool, 502
adverse food reactions
children, 123
food allergy see food allergy
food intolerance, 124
food-sensitive enteropathy, 129
immune response to dietary antigen, 135–9
ageing and energy restriction, tissue gene expression, 99
AKI see acute kidney injury (AKI)
albumin flux and capillary permeability, 29, 30
alcohol
and blood lipids, 106
and blood pressure, 106
and body weight, 105–6
coronary heart disease, 315–16
diabetes mellitus, 216
and glucose metabolism, 106
metabolism, 104–5
alcoholic steatohepatitis (ASH), 201–2, 202
alkaline phosphatase, 336, 342
allogeneic bone-marrow transplantation
(allo-HSCT), 259–60
American College of Gastroenterology Task Force, 189
American Society of Parenteral and Enteral Nutrition, 169
amino acid metabolism, liver disease, 199, 199–200, 200
amino and organic acid disorders, 467
anabolic androgen steroid (AAS), cancer patients, 416–17
anaphylactic/immediate hypersensitivity, 125
anorexia/cachexia syndrome (ACS), cancer, 169
anorexia nervosa
bone disease, 346
classification and features, 109–10
diagnostic criteria, 109
history, 111
incidence and prevalence, 112
malnutrition, 115
medical complications, 113
puberty, 445
weight recovery
maintenance of recovered nutritional status, 120
refeeding risk, stabilisation and management, 119
weight and nutritional status, restoration, 119–20
anorexia of psychological origin and refeeding syndrome, case study, 504–6, 505, 506
anthropometric measurements, kidney patients, 232
anticancer treatment, nutritional support guidelines, 169
antimicrobial therapy, gastrointestinal infections, 381, 382
antioxidant
cancer patients, 418
coronary heart disease, 314–15
defences and impact, immune and inflammatory systems
anti-inflammatory immunoenhancing effects, 287, 290
components, metabolic interrelationships, 287, 288
glutathione role, 285
 glutathione synthesis, nutrients and pronutrients, 287, 288
infection and trauma, 286
parenteral feeding solutions, PUFAs, 286
transcription-factor activation, 284, 290–291
vitamin B₆, 289–90
vitamin C intake, 288–9
vitamin E intake, 287–8
appetite
alteration, proinflammatory cytokines, 279
proinflammatory cytokines, 279
regulation, in eating disorders, 114–15, 118
stimulants, cancer patients, 415–16
aquaporin, 34
L-arginine, cardiovascular disease, 325
arginine, immunonutrition, 158
arsenic, cardiovascular disease, 324
arterial underfilling, 44
Arthus reaction, 125
artificial nutrition
cancer and terminal illness, wasting disorders, 169–70
dementia, 168–9
diabetes mellitus, 217
ethical principles, 167–72
inflammatory bowel disease, 187–8
malnutrition in hospitalised patient, 171–2
pancreatitis

© 2013 The Nutrition Society. Published 2013 by Blackwell Publishing Ltd.
artificial nutrition (cont’d)
  acute, 223–7
  chronic, 227–8
  persistent vegetative states, 170–171
  stroke, 167–8
artificial nutrition and hydration (ANH), 162, 164–6
aspiration pneumonia, enteral feeding, 147
atherosclerosis
  cardiovascular disorders, 301
  endothelium, 301
  fatty streaks, 301
  nutritional factors role, 302
  plaque, 301, 302
  saturated fat, effects, 306
  stable and unstable plaques, 302
autologous bone-marrow transplantation (a-HSCT), 260
bacterial contamination, food intolerance, 124
bacterial diarrhoea, 380
Balthazar-Ranson Score, pancreatitis, 226
bariatric surgery, 75–7
basal metabolic rate (BMR), 5, 52
  Schofield equations, 505
  under-nutrition, 83, 86, 87, 88, 90
B cells, dietary antigen, 137
beta-carotene, cystic fibrosis, 497
binge-eating disorder
  classification and features, 111, 111
  history, 111
  incidence and prevalence, 112–13
  medical complications, 114
  nutritional management, 120–121
  nutritional problems, 117
bioelectrical impedance phase angle, 402
bioethics, 161
bisphosphonates, osteoporosis, 337
blood pressure regulation, nutritional factors, 319–20
body cell mass (BCM), 203
  and survival, HIV-associated wasting, 366
body composition, 65–6
  childhood growth
    nutrient restriction and critical growth periods, 433, 431–2
    nutrient stores, 430, 430
  organ systems and nutrient partitioning, 430, 431
  sexual dimorphism, 432, 432
  HIV infection, 367–8
  measurements, 24–5
  tuberculosis, 377
  under-nutrition, 82
body electrolyte content and concentration, 31–2, 32
body mass index (BMI), 65, 98
  charts
    boys, 472
    girls, 471
  COPD-related mortality, 269
  girls and boys, 424, 425, 450, 452, 458
  WHO classification, of overweight and obesity, 48
body temperature alteration, proinflammatory cytokines, 279
body water compartments
  albumin flux and capillary permeability, 29, 30
  electrolyte concentrations, 28
  and electrolytes, in starvation and injury
    extracellular fluid, 36–7
    interstitial fluid, 37, 39
    intracellular fluid, 37
endothelial glyocalyx, 29
hydrostatic and oncotic pressure gradients, fluid movements, 29
interstitial space, 29
regulation
  body fluid osmolarity, 33, 33–4
  effective circulatory volume, 34–5, 35
  plasma osmolarity and sodium concentration, thirst stimulation, 35
  renal sodium excretion, efferent signals, 35
  thirst regulation and water balance, 35
  thirst stimulation, hypovolaemia, 35–6
  volume obligatoire, 33
Starling’s equation, 28
third space, 30
two-pore theory, 29–30
body weight and alcohol, 105–6
bone disease
  corticosteroid-induced, 343–4
  hypoparathyroidism and genetic forms, 337
  osteoporosis, 337
  post-transplant, 344–5
  vitamin D-deficient rickets and osteomalacia, 336–7
bone-marrow transplantation, 258, 259
bone metabolism, 327–9
bone-mineral density (BMD), 338
bone ultrasound, 338
bowel disease, case study, 508–12, 510
branched-chain amino acids (BCAAs), 205
  cancer patients, 416
breast-feeding
  breast milk
    composition, 437, 438
    consumption, 438–9
    establishment, 437–8
    health gains, 437
  HIV infection, 375
  brown adipose tissue (BAT), thermogenesis, 52–3
bullia nervosa
  classification and features, 110
  diagnostic criteria, 110
  history, 111
  incidence and prevalence, 112
burn injury, case study, 513–15
 cachexia, under-nutrition, 81, 82
calcium
  cardiovascular disease, 324
  chronic kidney disease, 248
  mineral-ion homeostasis, skeleton, 329, 330, 331, 332
  calcium balance, 329, 330
  dietary sources, 332
  estimated average requirement (EAR), 331
  impair calcium retention, dietary factors, 333
  metabolism, 329, 330
  recommended dietary intake (RDI), 331
  calciotriol, 337
cancer, artificial nutritional support, 169–70
cancer cachexia
  classification, 387
  definition and prevalence, 386–7
  hormonal milieu, 395
  mediators
    catabolic factors, 397–9
    cytokines, 395–7, 396, 398
iatrogenic malnutrition, 399–400, 399–402
malabsorption, 399–402
metabolic competition theory, 388
metabolic pathways, alterations
  acute-phase response, 394
  carbohydrate metabolism, 390–392
  energy balance, 389–90, 390, 391
  lipid metabolism, 392–3
  protein metabolism, 393–4
prevalence and severity of weight loss, 388
under-nutrition, 388–9
vitamin and mineral deficiencies, 394–5
cancer, nutritional support
  combined approach
    adenosine 5′-triphosphate, 418
    anabolic agents, 416–17
    antioxidant, 418
    appetite stimulants, 415–16
    nonspecific immune modulators, 417–18
    proteasome inhibitors, 418
  energy, 412
  fat, 412–13
  glucose, 413–14
home parenteral nutrition and enteral nutrition, 409, 409–10, 410, 411
malnutrition
  and chemotherapy, 403
  and outcome, 402–3
  and quality of life, 403
n-3 enriched enteral nutrition, 408–9
nutritional status
  chemotherapy/radiotherapy, 404
daily protein turnover, 407
enteral nutrition, 404
immunological response, 405
vs. non-cancer patients, 405
nutritional variables, 406
protein kinetic responses, 404–5
standard oral diet, 404
total parenteral nutrition (TPN), 403, 404
whole-body potassium (WBK), 404
protein, 413
supplemental parenteral nutrition, 411–12
surgery
  enteral nutrition, 407
  enteral tube feeding vs. parenteral nutrition, 407, 408
outcome, 407–8, 409
parenteral nutrition, 406–7
tumour growth, 414–15
water, 413–14
carbohydrate metabolism
  cancer cachexia, 390–392
disorders, 468
liver disease
  acute liver failure, 197–8
  cirrhosis, 198
  surgery and transplantation, 198
  cardiac alterations, obesity, 68
  cardiac cachexia and nutrition, 322
chronic kidney disease (CKD)
  diabetes mellitus, 243–5
  with steroids, 243–5
chronic kidney disease, 242–3
  and micronutrients
    L-arginine, 325
carnitine, 325
chronic kidney disease (CKD) (cont’d)
intradialytic parenteral nutrition, 250
kidney formulas, 250
oral nutritional supplementation, 250
PEM treatment, 249
pharmacological therapies, 250
total enteral/parenteral nutrition, 250

nutritional therapy, rationale and goals, 236
phosphate and calcium, 247–8
potassium, 248
progression, nutritional factors
diabetes mellitus, 239
dyslipidaemia and dietary fat, 237
obesity, 238–9
phosphate intake, 237
protein intake, 236–7
systemic hypertension, 237–8, 238

protein–energy malnutrition
adequacy of dialysis sessions, 240
chronic uraemia, causes and consequences, 240
classification, 242
detection and definition, 241–2
inflammation role, 241
metabolic acidosis, 240
nomenclature, 242, 242
nutrient metabolism, changes, 240–241
reduced food intake, 239–40
secondary hyperparathyroidism, 243
sodium and fluids, 248
vitamins, 248–9
chronic lymphocytic leukaemia (CLL), 255–6
chronic myeloid leukaemia (CML), 255
chronic obstructive pulmonary disease (COPD)
chronic bronchitis and emphysema, 267
classifications, pink puffer and blue bloater, 267
dietary practices, 271
health-related quality of life, 269–70
malnutrition
aetiology, 267, 267
prevalence, 269
mortality and morbidity, 268–9, 269
muscle function and exercise performance, 268
nutritional intervention, outcomes
composition of nutritional supplements, 272–3
disease (inflammatory process), 273
nutritional support, 273–4
oral nutritional supplements (ONSs), 271
physical activity, 274
weight gain, 271–2
obesity paradox, 269
weight loss and muscle wasting, causes
altered substrate metabolism, 270
energy metabolism, 270
reduced dietary intake, 270–271
chronic under-nutrition (CED), 88, 93–4
chylomicrons, 309
cirrhosis, 195, 195–6
carbohydrate metabolism, 198
energy requirements, 197, 197
fat metabolism, 198
nutritional therapy, 203, 203–5, 205
protein and amino acid metabolism, 199, 199
sodium and water metabolism implications, 44
cis-fatty acids, 308
clarithromycin, cancer patients, 418
celiac disease, 131, 134
characteristics, 178
diagnosis and screening, 180
diseases associated with, 179
epidemiology, 178
food chart, 181
gluten-free brands, 181, 181
pathogenesis, 178–9
spectrum of gluten sensitivity, 179
symptoms and signs, 180
therapeutic failure, 182
treatment, 180–182, 181, 181
coenzyme Q_{10} (ubiquinone), cardiovascular disease, 324–5
compensatory anti-inflammatory response syndrome (CARS), 280, 281
conflicts, 172–3
congestive heart failure, sodium and water metabolism
implications, 44
conjugated linoleic acid (CLA), immunomodulatory effects, 295
consent and competence, 165–6
conspiration, enteral feeding, 147
continuous ambulatory peritoneal dialysis (CAPD), 232, 240, 246
COPD see chronic obstructive pulmonary disease (COPD)
copper, cardiovascular disease, 324
cord-blood transplantation (CBT), 260
coronary heart disease
dietary factors
alcohol, 315–16
antioxidants, 314–15
dark chocolate, 316–17
fibre, 315
fish, n-3 fatty acids, and sudden death, 317–18
garlic, 316
Mediterranean diet, 318, 318–19
nuts, 316
plant sterols and stanols, 316
prevention, 325
soy protein, 315
tea, 316
weight-reduction diets, 319
and dietary lipids
cholesterol, 306–7
cis-and trans-fatty acids, 308, 308
food sources, 303
lipid types, 303, 303
monounsaturated fats, 307–8
plasma cholesterol and atherosclerosis, saturated fat effect, 306
polyunsaturated fats, 307, 307
and lipid-modifying drugs, 311, 311–13
lipid risk factors
high-density lipoprotein, 313–14
triacylglycerols, 314
corticosteroid-induced bone disease
direct effects on bone cells, 344
GC excess, bone remodelling, 344
osteoporosis, prevention and treatment, 344
PTH, 343–4
corticosteroids, cancer patients, 415–16
cost containment, ethics, 162
cow’s milk
allergy, 130–131
gastro-oesophageal reflux, 128
composition, 438
cow’s milk-sensitive enteropathy (CMSE), 131
C-reactive protein (CRP), 233
Crohn’s disease, 183 see also inflammatory bowel disease (IBD)
  case study, 503–4, 504, 508–9
  enteral nutrition, 188–9
crystalloids, 38, 39
cyclooxygenase (COX-2) inhibitors, cancer patients, 417
cyproheptadine hydrochloride, cancer patients, 416
cystic fibrosis (CF)
  definition and pathology, 486–7, 487
  energy balance, 488
  gastrointestinal features
    distal intestinal obstruction syndrome, 489–90
    fibrosing colonopathy, 490
    gastro-oesophageal reflux, 490–491
    liver disease, 490
    meconium ileus, 489
    pancreatic insufficiency, 488–9
    pancreatitis, 489
  incidence, 487
  infant feeding, 499
malnutrition
  dietary intake, 491
  energy losses, 491
  energy requirements, 491
minerals, 499
nutritional complications
  cystic fibrosis-related diabetes, 491–2
  eating disorders, 492
  fertility issues, 492–3
  lung transplantation, 493
  osteoporosis, 492
nutritional management, 495
nutritional status, assessment
  body composition and anthropometry, 493
  dietary assessment, 494
  energy requirements, 493–4
  malnutrition, categories, 494
nutritional support
  diet and nutritional supplements, 494
  enteral nutrition, 495
  enzyme sources, 496
  pancreatic enzyme therapy, 495–6
respiratory features, 487–8, 488
survival, 486–7
vitamin supplementation
  multivitamins, 498
  recommendations, 497
  vitamin A and beta-carotene, 497
  vitamin D, 498
  vitamin E, 498
  vitamin K, 498
  water-soluble vitamins, 498
cystic fibrosis-related diabetes (CFRD), 491–2
cystic fibrosis transmembrane regulator protein (CFTR), 486–7
cytokines
  biology, fatty acid composition, 291, 292
  cancer cachexia
    IL-1 and IL-6, 397
    interferon gamma (IFNγ), 397
    mechanism, 398
  nutritional and metabolic disturbances, 395
  protein, carbohydrate, and lipid metabolism, 396
  TNFα, 396–7
  control systems, 280–281
  damaging and life-threatening effects
    cell biology, transcription factors activation, 284
    individual’s genotype, adverse effects, 281–2
    effects, 278
  HIV-associated wasting, 369
  production, fats influence, 293
  response, malnutrition influence on
    protein-energy malnutrition, 284
    vitamin A deficiency, 284–5
  cytotoxic hypersensitivity, 125
dark chocolate, coronary heart disease, 316–17
delayed hypersensitivity/cell-mediated immunity, 125
dementia, artificial nutritional support, 168–9
dermatitis herpetiformis, 179
diabetes mellitus
  apps, 219
  chronic kidney disease, 239
  diagnosis, 211, 211–2
  diet
    alcohol, 216
    artificial nutrition, 217
    carbohydrate, 215–16
    carbohydrate-counting regimens, 215
    composition and properties, 215–16
    infections, 218
    intensive care, 217
    nephropathy, 218
    neuropathy, 218
    newborn infant of diabetic mother, 217
    pregnancy, 216
    retinopathy, 217–18
    surgery, 217
drugs, 213–14
glycaemic control, nutrition, and insulin, 209
  glucose transporters, 210
  insulin resistance, 210–211
  insulin-signalling pathways, 210
  insulin regimens, 213
  long-acting drugs, research, 219
  management and diet role, 212, 212
  monitoring and follow-up, 218–19
  oral drugs, 213–14, 214
  pathogenesis and types, 209
  physical activity, 214–15
  poor metabolic control, consequences, 211
  presentation, 211
  prevalence, 208–9
  transplantation, 219
  type 2, 102–3
diabetic kidney disease (DKD)
  definition, 236, 237
  dietary prescription, 245
  progression, nutritional factors, 236–9
  Diagnostic and Statistical Manual of Mental Disorders
    (DSM IV-TR), eating disorders, 108, 109–11
diarrhoea
  enteral feeding, 147
  infectious, 380–381, 382
  sodium and water metabolism implications, 44
diarrhoeal disease, acutely ill child, 463–5
dietary antigen, immune response, 135–9
Dietary Approaches to Stop Hypertension (DASH) diet
  blood pressure reduction, 320
  composition, 238
dietary history, nutritional assessment, 22, 22

disease, nutrition practice see health and disease, nutrition practice

distal intestinal obstruction syndrome (DIOS), cystic fibrosis, 489–90

diverticular disease

definition and epidemiology, 191

dietary fibre, 191–2

docosahexaenoic acid, 307

docosapentaenoic acid, 307

dronabinol

cancer patients, 416

HIV-associated wasting, 372

dual-energy X-ray absorptiometry (DEXA) bone density, 337

dumping syndrome see post-pyloric feeding

dyslipidaemia, 311

chronic kidney disease, 237, 246–7

and insulin resistance, 103

dysphagia, 167, 176

case study, 515–16

causes, 177

management, 177

eating disorders

aetiology, 112

classification and features, 108

anorexia nervosa, 109, 109–10

bulimia nervosa, 110, 110

EDNOS and binge-eating disorder, 111, 111

history, 111–12

incidence and prevalence

anorexia nervosa, 112

bulimia nervosa, 112

EDNOS and binge-eating disorder, 112–13

medical complications

binge eating, 114

compensatory behaviours, 114

starvation and low weight, 113–14

nutritional management

binge eating, 120–121

compensatory behaviours, 120

restoring appetite regulation, 118

weight recovery, 119–20

nutritional problems

appetite regulation, 114–15

binge eating, 117

compensatory behaviours, 117

starvation and low weight, 115–17

schoolchildren and adolescents, 444–6

Eating Disorders Not Otherwise Specified (EDNOS) and binge-eating disorder

classification and features, 111, 111

incidence and prevalence, 112–13

egg allergy, 134

eicosanoids, 307

eicosapentaenoic acid (EPA), cancer patients, 417

elderly populations

derhydration, 45

reduced calcium bioavailability, factors, 347

under-nutrition, 88–9

electrolytes see also water and electrolytes

body secretions, 4

effect of disease, 3–4

starvation and low weight, nutritional impact, 115–17

emphysema, 267

encephalopathy, 205

endochondrial bone formation, cellular interactions, 328

endocrine abnormalities, HIV-associated wasting, 369

endocrine disorders, obesity, 59, 60, 61

endocrine system, eating disorders, 113

endocrinopathies, 59

energy deficiency, 81

energy, effect of disease, 5, 5–6

energy intake and longevity, 98–9, 99

energy metabolism

chronic obstructive pulmonary disease, 270

HIV infection, 368

under-nutrition

basal metabolic rate (BMR), 83

body weight with negative energy balance changes, in twins, 83, 83

fat-free mass (FFM), 83

infection and injury, 86, 87

lowered energy expenditure, negative energy balance, 84, 84

physical activity, 84

thermogenesis, 83–4

total 24-hour energy expenditure, components, 83

energy requirements

cystic fibrosis, 491, 493–4

equations, 141

liver disease

acute liver failure, 196

cirrhosis, 197, 197

surgery and transplantation, 197

pancreatitis, 225–6

enhanced recovery after surgery (ERAS), 358, 358–9

enteral nutrition

anorexia of psychological origin and refeeding syndrome, 505, 506

cancer patients

nutritional status, 404–7

vs. parenteral nutrition, 407, 408

surgery, nutritional support, 407

cirrhosis, 203

cystic fibrosis, 495

dementia, 168

immune function, 296

pancreatitis, 224–5

sick child, routes of access, 459

enteral tube feeding (ETF)

advantages and disadvantages, 148

artificial enteral access, selection, 146

aspiration pneumonia, 147

complications, 150, 151–2

contraindications, 144

diarrhoea and constipation, 147

disease-specific supplements, 149

drug administration

adding drugs, 153

alternative routes of delivery, 153

controlled-release products, 152

crushing, tablet, 150

cytotoxic drugs, 152

enteric coating, 152

gelatin capsules, 150, 152

hormonal drugs, 152–3

liquid formulations, 150

feeding rate, 150

feeding routes, 146, 146

gastrostomy tube placement, contraindications, 146
HIV-associated wasting, 370–371
monitoring, 150
nausea and vomiting, 147
physical characteristics, 147–8
post-pyloric feeding, 147
solutions, 148–9, 149
eosinophils, food allergies, 138
erythropoietin, 7
ETF see enteral tube feeding (ETF)
ethics and nutrition
advanced decisions/directives/proxies, 166
artificial nutritional support
cancer and terminal illness, wasting disorders, 169–70
dementia, 168–9
malnutrition in hospitalised patient, 171–2
persistent vegetative states, 170–71
stroke, 167–8
artificial nutrition and hydration, 162, 164–5
bioethics, 161
clinical guidelines, 173, 173–4
conflict, 172–3
consent and competence, 165–6
cost containment, 162
doctor–doctor relationship, 163
doctor–patient relationship, 161
duty-based moralist, 163–4
four-principle approach, 163–4, 173
autonomy, 162, 163, 168, 172, 173
beneficence, 162, 163, 171, 173
justice, 163, 172, 173
nonmaleficence, 162, 163, 171, 173
futility and net patient benefit, 167
history, 162–3
Lasting Power of Attorney (LPA), 166
medical technology and pharmacology, explosion, 161
oral nutrition and hydration, basic care, 164
paternalism, 163
rights-based moralist, 164
time-limited trials of treatment, 166
utilitarian/goal-based moralist, 164
European Society for Clinical Nutrition and Metabolism (ESPEN), 235, 235, 386
extracellular fluid (ECF), 27, 28, 31, 32, 36–7
ezetimibe, coronary heart disease, 313
fat
malabsorption, rickets/osteomalacia, 340–341
metabolism
liver disease, 198
proinflammatory cytokines, 279
fat-free mass (FFM), 83, 268
fatty acid
composition, cytokine biology, 291, 292
types, 303
feeding route effects, nutrient requirements, 8–10
feeding schedules, nutrition practice, 12
feeding tubes, 146, 148
fertility issues, cystic fibrosis, 492–3
fibrates, coronary heart disease, 311–12
fibre
coronary heart disease, 315
diabetes mellitus, 216
and diverticular disease, 191–2
fibrosing colonopathy, 490
fish oil, 293
cancer patients, 417–18
coronary heart disease, 317–18
fluids
chronic kidney disease, 248
and electrolytes
effect of disease, 3–4, 4
starvation and low weight, nutritional impact, 117
replacement, diarrhoeal disease, 464, 464–5, 465
therapy, 41–3
[18]2-fluoro-2-deoxy-D-glucose (FDG), 415
folate
chronic kidney disease, 248
supplementation, cardiovascular disease, 323
food allergy
celiac disease, 131
cow's milk, 130–131, 131
diagnostic criteria, 128–9
dietary allergy, failure to thrive, 132–3
egg, 134
late-onset symptoms
chronic constipation, allergic dysmotility, 127, 128
gastro-oesophageal reflux, 127, 127, 128
mast cells and eosinophils, 138
multiple-food allergy, 135
oesophagus in dysmotility, 131
peanuts, 134–5
quick-onset symptoms, 126–7
soya, 131, 134
types of
anaphylactic/immediate hypersensitivity, 125
clinical manifestations, 126
cytotoxic hypersensitivity, 125
delayed hypersensitivity/cell-mediated immunity, 125
IgE-mediated and non-IgE-mediated, 125–6
immune-complex hypersensitivity, 125
wheat, 134
food intolerance, 124
irritable bowel syndrome, 190
management, children, 466–7
food poisoning, 380
food-sensitive enteropathy, 129, 130
free fatty acid, insulin resistance, 103
fructose and sorbitol malabsorption, irritable bowel syndrome, 190
garlic, coronary heart disease, 316
gastric and jejunal feeding, 9–10
gastric pacing, obesity, 78
gastrointestinal tract
celiac disease, 178–82
diverticular disease, 191–2
dysphagia, 176–7, 177
fluid flux, 31, 31
function, salt and water overload, 40
gastro-oesophageal reflux disease (GORD), 177
gene expression, research, 192
infections
antimicrobial therapy, 381, 382
definition and aetiology/pathogenesis, 379–80
diet, 383
epidemiology, 380–381
nutritional and metabolic management, 381
oral rehydration solutions, 382–3, 383
organisms, 380
Index

Gastrointestinal tract (cont’d)
- inflammatory bowel disease, 183–9
- irritable bowel syndrome, 189–91
- maturation, paediatric nutrition, 434
- mucositis, haematological malignancies, 257–8, 258
- oesophagus and stomach, cancer, 177–8
- radiation tolerance, 400
- short-bowel syndrome, 178
- starvation and low weight, eating disorders, 113–14
- tropical enteropathy and tropical sprue, 182–3

Gastro-oesophageal reflux (GOR), 490–491
- food allergy, 127, 127, 128
- gastro-oesophageal reflux disease (GORD), 177

Gastroplasty, 76

Gastrostomy, 459

Gestational diabetes mellitus (GDM), 209

Ghrelin, cancer patients, 416

Glasgow Prognostic Score, 403

Glasgow score, pancreatitis, 222

Glomerular filtration rate (GFR), 37, 230, 236

Glucocorticoid (GC) excess, bone remodelling, 344

Glucose
- cancer patients, 413
- control, surgical patient, 357
- metabolism and alcohol, 106
- cancer patients, 391–2
- paediatric nutrition, 461–2
- glucose transporters (GLUT), 210
- glutamine, 91–2
- immunonutrition, 158
- glutathione, 499
- antioxidant defence, 285, 287, 288, 290
- gluten-sensitive enteropathy see coeliac disease
- glycaemic control, diabetes mellitus, 209–11
- glycaemic index, 216
- glycated haemoglobin (HbA1c), 211–12, 245

Graft-versus-host disease (GVHD), HSCT, 259, 261

Growth hormone (GH)
- cancer patients, 417
- HIV-associated wasting, 371–2, 372
- obesity, 61

Haematological malignancies
- disease-dependent and treatment-dependent nutritional risks, 254
- lymphoproliferative disorders
  - acute lymphocytic leukaemia, 255
  - chronic lymphocytic leukaemia, 255–6
  - Hodgkin’s lymphoma, 256
  - malignant lymphomas, 256
  - multiple myeloma, 256
  - non-Hodgkin’s lymphoma, 256
- myeloproliferative disorders
  - acute myeloid leukaemia, 254–5
  - chronic myeloid leukaemia, 255
  - myelodysplastic syndrome, 254

Nutritional intervention
- gastrointestinal tract, mucositis, 257–8, 258
- haematopoietic stem-cell transplantation, 258–62
- rationale, 257
- strategy, 263, 264
- treatment-related nutritional problems, 258
- haematopoietic stem-cell transplantation (HSCT)
- acute and chronic graft-versus-host disease, 261
- a-HSCT, 260
- allo-HSCT, 259–60
- altered metabolism, 261
- cord-blood transplantation, 260
- glutamine supplementation, 264
- n-3 fatty acids, 264
- nutritional and metabolic support, 260–261, 262–3
- nutritional status assessment, 262
- peripheral blood-progenitor cell transplant, 260
- veno-occlusive disease of liver, 261–2

Haemorrhagic disease of newborn (HDN), 441

Harris-Benedict equation
- energy requirement, 90, 141
- resting energy expenditure, 104

Health and disease, nutrition practice, 1
- energy, 5, 5–6
- feeding schedules, 12
- fluid and electrolytes, 3–4
- frequency distribution of nutrient requirements, 3
- management pathways, 13
- metabolic blocks
  - acquired metabolic blocks, 6–8, 7, 7
  - inborn errors of metabolism, 6
- phase of disease, effect, 10–12
- protein, 4–5
- route of feeding, effect
  - cutaneous (skin), 10
  - gastric and jejunal feeding, 9–10
  - parenteral nutrition, 8–9
  - peritoneal, 10
  - rectal, 10
  - subcutaneous, 10
- spectrum of nutritional problems
- potassium and phosphate omitting from parenteral nutrition regimen, effect of, 3
- under-nutrition, physical and psychosocial effects of, 2
- structure and function, 12–13

Heart and blood vessels

Atherosclerosis
- cardiovascular disorders, 301
- endothelium, 301
- fatty streaks, 301
- nutritional factors role, 302
- plaque, 301
- stable and unstable plaques, 302

Coronary heart disease see coronary heart disease diet
- and chronic heart failure, 321–2
- and hypertension, 319–21
- and peripheral vascular disease, 321
- and stroke, 321

Lipoprotein metabolism, 310

Coronary heart disease and lipid risk factors, 313–14

Dyslipidaemia, 311

Endogenous pathway, 310

Exogenous pathways, 309–10

Lipid-modifying drugs and coronary heart disease, 311

Reverse cholesterol transport, 310–311

Micronutrients and cardiovascular disease, 322–5

Plasma lipoproteins
- composition, 309
- structure, 308

Heart failure and diet, 321–2
heat-shock proteins (HSPs), 281
hepatitis, 200
high-density lipoprotein (HDL), 309, 310, 313–14
highly active antiretroviral therapy (HAART), HIV infection, 364, 365
HIV infection see human immunodeficiency virus (HIV) infection
Hodgkin’s lymphoma, 256
home parenteral nutrition (HPN), 409–10, 410, 411
hormonal axes disturbances, obesity, 60
hormonal mediators, under-nutrition, 86–8
HSCT see haematopoietic stem-cell transplantation (HSCT)
human immunodeficiency virus (HIV) infection
body-composition change, 367–8
breast-feeding, 375
clinical features, 364
energy metabolism, 368
fat and carbohydrate metabolism, 369
HIV-associated wasting
body cell mass (BCM) and survival, 366
clinical importance, 366–7
cytokines, 369
definition, 365–6
endocrine abnormalities, 369
enteral tube feeding, 370–371
indicators, 366
nutritional counselling, 369–70
oral supplements, 370
parenteral nutrition, 371
pathogenesis, 365
pharmacological therapy, 371–2
indicators, 366
indicators, 366–7
reduction of blood pressure, 320–321
weight change, 367, 367
hypertension
chronic kidney disease, 237–8, 238
and diet
blood pressure regulation, nutritional factors, 319–20
reduction of blood pressure, 320–321
and insulin resistance, 104, 105
hyperalbuminaemia, 41
hypoglycaemia, cancer patients, 392
hypophagia and cancer cachexia
alimentary-tract organs, radical resection, 399
chemotherapy, negative side effects, 401
combinations of therapy, negative effects, 400
gastrointestinal tract, radiation tolerance, 400
radiotherapy, 399–400, 400
hypothalamic–pituitary axis (HPA), obesity, 59
hypovolaemia, thirst stimulation, 35–6
iatrogenic malnutrition, cancer cachexia
hypoxia, 399–400
malabsorption, 401–2, 402
ileotyphlitis, 257, 258
immune and inflammatory systems
antioxidant defences and impact
anti-inflammatory immunoenhancing effects, 287, 290
components, metabolic interrelationships, 287, 288
glutathione role, 285
glutathione synthesis, nutrients and pronutrients, 287, 288
immunomodulation, 286–7, 287
infection and trauma, 286
oxidant damage risks, PUFAs, 286
transcription-factor activation, 290, 290–291
vitamin B6, 289–90
vitamin C intake, 288–9
vitamin E intake, 287–8
response to activation, 277
cytokines
control systems, 280–281
damaging and life-threatening effects, 281–3, 284
effects, 278
response, malnutrition influence on, 283–5
immune-enhancing diets, 298–9
innate response, 277
lipids, immunomodulatory effects, 291–5
nutritional provision and immune function and patient outcome
enteral and parenteral feeding, 296
total parenteral nutrition, 296–8
proinflammatory cytokines
adverse effects, body composition, 283
body temperature and appetite, alteration, 279
liver protein synthesis, changes, 280, 280
metabolic changes, 278
physiological and metabolic effects, 278
production, physiological and metabolic acids, 279
protein and fat metabolism, changes, 279
trace-element and vitamin metabolism, changes, 279–80
response to activation, 277, 277–8, 278
immunocomplex hypersensitivity, 125
immune function, under-nutrition, 86
immune response, to dietary antigen
antigen presentation, epithelium, 136
B-cell responses, control, 137
B cells, skewing, 137
bystander tolerance, 138
innate immunity and evolutionary heritage, 135–6
lymphocytes differentiation, 136
mast cells and eosinophils, 138
mucosal IgA production, importance, 137
oral tolerance, 138–9
T cell distribution in intestine, 136
T_{hel} \text{ IL17} paradigm of T-cell responses and infectious exposures, 138–7
immunoglobulins (Igs), 277
IgA production, dietary antigen, 137
IgE
dietary antigen, 137
food allergies, 125–6
immunonutrition, 158
inborn errors of metabolism, 6
amino and organic acid disorders, 467
carbohydrate metabolism, 468
dietary management, 468–9
lipid metabolism, 468
phenylketonuria, 469, 469–70
infant, child, and pubertal (ICP) phases, 426, 427
infant feeding
bottled infants, weight gain, 441
breast-feeding, 437–9
complementary feeding, 439–41
cystic fibrosis, 499
dietary supplements
preterm and low-birth-weight infants, 442
vitamin drops, 442
vitamin K, 441–2
effect of feeding on growth, 441, 441
formula feeding, 438, 439
infants
catch-up and catch-down growth, 427, 428
of diabetic mother, 217
food allergies, 124, 127, 135
rickets, 339, 339–40
infectious diarrhoea, 380–383
infectious diseases
gastrointestinal infections, 379–83
human immunodeficiency virus infection, 364–75
malaria, 378–9
tuberculosis, 375–8
inflammation, chronic kidney disease, 241
inflammatory bowel disease (IBD)
clinical features and diagnosis, 184
definition, 183
epidemiology, 183–4
impaired nutrition, consequences, 187
malnutrition
increased metabolism, 185–6
intestinal protein losses, increased, 186
nutrient malabsorption, 186
pathogenic mechanisms, 185
poor nutrient intake, 185
protein–energy malnutrition, 185
micronutrient deficiencies
minerals and trace elements, 186–7
vitamins, 186
nutritional support
adjuvant therapy, artificial nutrition, 187–8
enteral nutrition, in Crohn’s disease, 188–9
pathogenesis, 184
treatment, 184
inflammatory systems see immune and inflammatory systems
injury
body water compartments and electrolytes, 36–7, 39
metabolic response, 36
innate immunity, dietary antigen, 135–6
insulin–like growth factor 1, 336
insulin regimens, 213
insulin resistance
HIV infection, 374
metabolic disorders
and dyslipidaemia, 103
factors, 101
hyperinsulinaemia, 101
and hypertension, 104
mechanisms, 105
pathophysiology, 100, 101
type 2 diabetes, 103
trauma, 353–4, 354
type 2 diabetes, 210–211
insulin-resistance syndrome, cancer patients, 395
interferon gamma (IFNγ), 397
interleukin 6 (IL-6), 397
intermediate-density lipoproteins (IDLs), 309
interstitial fluid, 37, 39
intracellular fluid (ICF), 32, 32, 37
intragastric balloon (IGB) therapy, obesity, 77–8
intravenous (IV) nutrition, recommended doses of vitamins
and trace elements, 9
iodine deficiency, children, 456
iron
cystic fibrosis, 499
deficiency, children, 454
supplementation, malaria, 379
irritable bowel syndrome (IBS)
definition, 189
dietary management, 190–191
epidemiology, 189
food intolerance, 190
nutritional consequences, 190
pathogenesis, 190
Rome criteria evolution, 189
jejunal feeding, 9–10
Karlberg infant, child, and pubertal (ICP) model, human
growth, 427
kidney
fluid flux, 30–31, 31
patients, nutritional assessment
anthropometric measurements, 232
biochemical indices, 232–3
food and nutrient intake, 232
functional indices, 233
subjective global assessment, 233
transplantation
nutritional management, 251
pre-transplant nutritional assessment, 251
lactic acidosis, HIV infection, 373–4
lactose intolerance, 124
lactose malabsorption, irritable bowel syndrome, 190
lead, cardiovascular disease, 324
leptin, 83
limb tissues, cross-sectional area calculation, 24
linolenic acid, 307
lipid emulsions, cancer patients, 412–13
lipid-mobilising factors (LMFs), 397–9
lipid-modifying drugs and coronary heart disease
ezetimibe, 313
fibrates, 311–12
nicotinic acid derivatives, 311
resins, 311
statins, 312–13
lipids
and coronary heart disease, 302–8
immunomodulatory effects
conjugated linoleic acid role, 295
cytokine production, 293
disease, in animal models and humans, 293–4
<table>
<thead>
<tr>
<th>Experimental studies, 294</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatty acid composition, cytokine biology, 291, 292</td>
</tr>
<tr>
<td>Human populations, experimental observation implications, 294–5</td>
</tr>
<tr>
<td>Inflammatory agents and diseases, 291–2</td>
</tr>
<tr>
<td>Membrane fluidity, 294</td>
</tr>
<tr>
<td>Proinflammatory cytokines and inflammatory agents, 292–3</td>
</tr>
<tr>
<td>Metabolism</td>
</tr>
<tr>
<td>Acute kidney injury, 234–5</td>
</tr>
<tr>
<td>Cancer patients, 392–3</td>
</tr>
<tr>
<td>Disorders, 468</td>
</tr>
<tr>
<td>Paediatric nutrition, 462</td>
</tr>
<tr>
<td>Lipodystrophy syndrome, HIV-associated</td>
</tr>
<tr>
<td>Abdominal magnetic resonance images, 373</td>
</tr>
<tr>
<td>Aetiology, 372–3</td>
</tr>
<tr>
<td>Features, 372</td>
</tr>
<tr>
<td>Treatment, 373</td>
</tr>
<tr>
<td>Liproteins</td>
</tr>
<tr>
<td>Composition, 309, 309</td>
</tr>
<tr>
<td>Metabolism, 310</td>
</tr>
<tr>
<td>Coronary heart disease and lipid risk factors, 313–14</td>
</tr>
<tr>
<td>Dyslipidaemia, 311</td>
</tr>
<tr>
<td>Endogenous pathway, 310</td>
</tr>
<tr>
<td>Exogenous pathways, 309–10</td>
</tr>
<tr>
<td>Lipid-modifying drugs and coronary heart disease, 311, 311–13</td>
</tr>
<tr>
<td>Reverse cholesterol transport, 310–311</td>
</tr>
<tr>
<td>Structure, 308</td>
</tr>
<tr>
<td>Liver disease</td>
</tr>
<tr>
<td>Acute</td>
</tr>
<tr>
<td>Acute liver failure (ALF), 200–201, 201, 202</td>
</tr>
<tr>
<td>Hepatitis, 200</td>
</tr>
<tr>
<td>Acute liver disease, 195</td>
</tr>
<tr>
<td>Cardiopulmonary exercise capacity, cirrhosis, 196</td>
</tr>
<tr>
<td>Chronic</td>
</tr>
<tr>
<td>Alcoholic steatohepatitis, 201–2, 202</td>
</tr>
<tr>
<td>Cirrhosis, 203, 203–5, 205</td>
</tr>
<tr>
<td>Nonalcoholic steatohepatitis, 202–3</td>
</tr>
<tr>
<td>Perioperative nutrition, 205</td>
</tr>
<tr>
<td>Transplantation, 205–6</td>
</tr>
<tr>
<td>Cirrhosis, 195, 195–6</td>
</tr>
<tr>
<td>Cystic fibrosis, 490</td>
</tr>
<tr>
<td>Nutritional risk, 193–4</td>
</tr>
<tr>
<td>Over-nutrition, 195</td>
</tr>
<tr>
<td>Pathophysiology and nutrient requirement</td>
</tr>
<tr>
<td>Carbohydrate metabolism, 197–8</td>
</tr>
<tr>
<td>Energy, 196–7, 197</td>
</tr>
<tr>
<td>Fat metabolism, 198</td>
</tr>
<tr>
<td>Protein and amino acid metabolism, 199, 199–200, 200</td>
</tr>
<tr>
<td>Vitamins and minerals, 200</td>
</tr>
<tr>
<td>Surgery and transplantation, 196, 196</td>
</tr>
<tr>
<td>Under-nutrition, 194–5</td>
</tr>
<tr>
<td>Liver transplantation, 196</td>
</tr>
<tr>
<td>Carbohydrate metabolism, 198</td>
</tr>
<tr>
<td>Energy requirements, 197</td>
</tr>
<tr>
<td>Fat metabolism, 198</td>
</tr>
<tr>
<td>Nutritional therapy, 205–6</td>
</tr>
<tr>
<td>Protein and amino acid metabolism, 199–200, 200</td>
</tr>
<tr>
<td>Low-density lipoprotein (LDL) cholesterol, 309, 310</td>
</tr>
<tr>
<td>Low-protein diet (LPD), chronic kidney disease, 237, 245–6</td>
</tr>
<tr>
<td>Lung</td>
</tr>
<tr>
<td>Acute lung injury, 274</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease see chronic obstructive pulmonary disease (COPD)</td>
</tr>
<tr>
<td>Malnutrition, 266</td>
</tr>
<tr>
<td>Respiratory disease, 266–7</td>
</tr>
<tr>
<td>Transplantation, cystic fibrosis, 493</td>
</tr>
<tr>
<td>Lymphoproliferative disorders</td>
</tr>
<tr>
<td>Acute lymphocytic leukaemia, 255</td>
</tr>
<tr>
<td>Chronic lymphocytic leukaemia, 255–6</td>
</tr>
<tr>
<td>Hodgkin’s lymphoma, 256</td>
</tr>
<tr>
<td>Malignant lymphomas, 256</td>
</tr>
<tr>
<td>Multiple myeloma, 256</td>
</tr>
<tr>
<td>Non-Hodgkin’s lymphoma, 256</td>
</tr>
<tr>
<td>Magnesium, cardiovascular disease, 324</td>
</tr>
<tr>
<td>Malabsorption, cancer</td>
</tr>
<tr>
<td>Drug-induced nutrient deficiencies, 402, 402</td>
</tr>
<tr>
<td>Incidences, 402</td>
</tr>
<tr>
<td>Intestinal enzyme deficiency, 401</td>
</tr>
<tr>
<td>Malaria</td>
</tr>
<tr>
<td>Clinical presentation and treatment, 378–9</td>
</tr>
<tr>
<td>Epidemiology and importance, 378</td>
</tr>
<tr>
<td>Micronutrients, 379</td>
</tr>
<tr>
<td>Protein–energy malnutrition, 379</td>
</tr>
<tr>
<td>Malignant lymphomas, 256</td>
</tr>
<tr>
<td>Malnutrition, 2</td>
</tr>
<tr>
<td>Cancer</td>
</tr>
<tr>
<td>and chemotherapy, 403</td>
</tr>
<tr>
<td>and outcome, 402–3</td>
</tr>
<tr>
<td>and quality of life, 403</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease, 267, 267, 269</td>
</tr>
<tr>
<td>Cystic fibrosis, 491, 494</td>
</tr>
<tr>
<td>Ethical principle, 171–2</td>
</tr>
<tr>
<td>Hospitalised patient, 171–2</td>
</tr>
<tr>
<td>Inflammatory bowel disease, 184–6</td>
</tr>
<tr>
<td>Older person, 506, 506, 507, 508</td>
</tr>
<tr>
<td>Time frame for management, 11, 11</td>
</tr>
<tr>
<td>and tuberculosis, 377</td>
</tr>
<tr>
<td>Malnutrition Universal Screening Tool (‘MUST’), 18, 20</td>
</tr>
<tr>
<td>Manganese, cardiovascular disease, 324</td>
</tr>
<tr>
<td>Mast cells and eosinophils, food allergies, 138</td>
</tr>
<tr>
<td>Meconium ileus, cystic fibrosis, 489</td>
</tr>
<tr>
<td>Median preoptic nucleus (MnPO), 35</td>
</tr>
<tr>
<td>Medical ethics see ethics and nutrition</td>
</tr>
<tr>
<td>Mediterranean diet, coronary heart disease, 318–19</td>
</tr>
<tr>
<td>Megestrol acetate</td>
</tr>
<tr>
<td>Cancer patients, 415</td>
</tr>
<tr>
<td>HIV-associated wasting, 371</td>
</tr>
<tr>
<td>Membrane fluidity, immune/inflammatory response, 294</td>
</tr>
<tr>
<td>Mendelian disorders, obesity, 57</td>
</tr>
<tr>
<td>Mental Capacity Act 2005 (MCA), 165</td>
</tr>
<tr>
<td>Metabolic acidosis, protein–energy malnutrition, 240</td>
</tr>
<tr>
<td>Metabolic blocks and nutritional requirements</td>
</tr>
<tr>
<td>Acquired metabolic blocks, 6–8, 7, 7</td>
</tr>
<tr>
<td>Inborn errors of metabolism, 6</td>
</tr>
<tr>
<td>Metabolic–competition theory, cancer cachexia, 388</td>
</tr>
<tr>
<td>Metabolic disorders</td>
</tr>
<tr>
<td>Alcohol</td>
</tr>
<tr>
<td>and blood lipids, 106</td>
</tr>
<tr>
<td>and blood pressure, 106</td>
</tr>
<tr>
<td>and body weight, 105–6</td>
</tr>
<tr>
<td>and glucose metabolism, 106</td>
</tr>
<tr>
<td>Metabolism, 104–5</td>
</tr>
<tr>
<td>Dietary management, 103–4</td>
</tr>
<tr>
<td>Energy intake, health, and longevity, 98–9, 99</td>
</tr>
<tr>
<td>Insulin resistance</td>
</tr>
<tr>
<td>and dyslipidaemia, 103</td>
</tr>
<tr>
<td>Factors, 101</td>
</tr>
<tr>
<td>Hyperinsulinaemia, 101</td>
</tr>
</tbody>
</table>
metabolic disorders (cont’d)
and hypertension, 104, 105
lipolysis, 102
pathophysiology, 100, 101
noncommunicable diseases, development, 97–8
obesity development, 98
type 2 diabetes mellitus, 102–3
WHO criteria, 100
metabolic syndrome, 99–100
metformin, 213
micronutrients and cardiovascular disease, 322–5
deficiency
children, 453–7
under-nutrition, 92, 92
and HIV, 374–5
and malaria, 379
Mifflin equation, energy requirements, 141
mineral-ion homeostasis, skeleton
calcium, 329, 330, 331, 331, 332
phosphorus, 331–2
preterm infants
biochemical changes, 342
radiological changes, 342–3
substrate delivery, 343
minerals and cardiovascular disease, 323–4
deficiencies, cancer patients, 395
eating disorders, 116–17
liver disease, 200
supplementation, cystic fibrosis, 499
Mini Nutritional Assessment (MNA), 17, 19, 507
monounsaturated fats and coronary heart disease, 307–8
multi-organ failure (MOF), acute pancreatitis, 220, 221
multiple myeloma, 256
muscular and nonmuscular limb tissues, cross-sectional area calculation, 24
musculoskeletal system, eating disorders, 113
myelodysplastic syndrome (MDS), 254
myeloproliferative disorders
acute myeloid leukaemia, 254–5
chronic myeloid leukaemia, 255
myelodysplastic syndrome, 254
nasogastric feeding, stroke, 167
nasogastric tubes, 146, 459
naso/orojejunal tubes, 459–60
natural resistance-associated macrophage protein 1 (NRAMP1), 282
negative energy balance, 83–4, 83–4
nephron, function and action, 230, 231
nephropathy, 218
neurological maturation, paediatric nutrition, 433, 433
neuropathy, 218
neutropaenic enterocolitis, 257
n-3 fatty acids, 307, 317–18
enteral nutrition, cancer patients, 408–9
immunonutrition, 158
inflammatory systems, 295
n-6 fatty acids, 307
inflammatory systems, 294, 295
nicotinic acid derivatives, coronary heart disease, 311
nitrogen balance
increasing protein (N) intake, effect, 4, 5
infant, 436
nitrogen, paediatric nutrition, 462
nonalcoholic steatohepatitis (NASH), 195, 202–3
nonessential amino acids, 91–2, 92
non-exercise activity thermogenesis (NEAT), 53
non-Hodgkin’s lymphoma, 256
nonsteroidal anti-inflammatory drugs (NSAIDs), cancer patients, 417
nuclear factor kappa B (NFκB), 283, 290
nutritional assessment, 15
clinical examination
body-composition measurements, 24–5
correction factors, 25
laboratory, 25
muscular and nonmuscular limb tissues, cross-sectional area calculation, 24
protein–energy malnutrition, 22
signs and nutritional causes, 23
trace-element deficiencies and manifestations, 24
vitamin deficiencies and manifestations, 23
clinical history
nutrient deficiencies, 21–2
protein–energy malnutrition, 21
diary history, 22, 22
nutritional pharmacology, 7
nutritional screening, 15
blood tests, 20, 21
Malnutrition Universal Screening Tool (‘MUST’), 18, 20
Nutritional Risk Screening-2002 (NRS-2002), 20
programme, 16
screening-tool selection, 16, 17
Short-form Mini Nutritional Assessment (MNA), 17, 19
Subjective Global Assessment (SGA), 17, 18
test, 16
nutritional support see also artificial nutrition
acute kidney injury, 235–6
anticancer treatment and haemopoietic cell transplantation, guideline recommendations, 169
arginine, 158
cancer patients see cancer, nutritional support
chronic kidney disease, 249–50
chronic obstructive pulmonary disease, 273–4
clinical nutrition at home, 156–7
decision tree for optimal route, 145
energy requirements, equations, 141
enteral tube feeding
advantages and disadvantages, 148
aspiration pneumonia, 147
diarrhoea and constipation, 147
drug administration, 150, 152–3
feeding rate, 150
feeding routes, 146, 146
monitoring and complications, 150
nausea and vomiting, 147
physical characteristics, 147–8
post-pyloric feeding, 147
solutions, 148–9, 149
FAO/WHO/UNU equation, 141
fat-free mass, 142
glutamine, 158
Harris–Benedict equation, 141
hyperalimentation, 141
immunonutrition, 158
inflammatory bowel disease, 187–9
meeting nutritional needs, 140–142
Mifflin equation, 141
Index

n-3 fatty acids, 158
nutrition support team, 157–8
oral feeding and oral nutritional supplements, 142–4, 143
Owen’s equation, 141
parenteral nutrition
catheter access, 154
indications, 153
monitoring and complications, 154–5
solutions, 154
perioperative care, 354–60 see also perioperative care,
nutritional support
refeeding syndrome, 157
sepsis, 156
sick child, 457–70
nutrition screening tool for adults, 502
nuts, coronary heart disease, 316
obesity see also over-nutrition
case study, 516–17
childhood, 479, 480–481, 482–3
chronic kidney disease, 238–9
development, 98
endocrine disorders
endocrine changes, 59, 60, 61
endocrinopathies, 59
hormonal axes, disturbances, 60
identification and management, algorithms, 70–71
genetic epidemiology, 54–5
molecular epidemiology
candidate gene selection, 55
functional candidate genes, 56
Mendelian disorders, 57
positional candidate genes, 56, 58–9
quantitative trait loci (QTLs), 58
single gene-mutation mouse models, 55–6, 56
oligogenic disease, 54
obesity-related glomerulopathy (ORG), 238
oesophageal cancer, 177–8
oral feeding and oral nutritional supplements, 142–4, 143
oral nutritional supplements (ONSs), 143–4
chronic kidney disease, 250
chronic obstructive pulmonary disease, 271
oral nutrition and hydration, basic care, 164
oral rehydration solutions (ORSs), 382–3, 473, 474
compositions, 383
oral tolerance, to dietary antigens, 138–9
orlistat, 73–4
osmolarity control, body fluid, 33, 33–4
osteocalcin, 336, 336
osteomalacia
adults, 340
causes, 341
definition, 338
treatment, 336–7
osteoporosis
anorexia nervosa, 113
with chronic disease, 345–6
cystic fibrosis, 492
fragility fracture sites, 346
steroid-induced, prevention and treatment, 344
treatment, 337
over-nutrition
aetiology
appetite control, food and nutrient influences, 51
drugs, weight gain, 64
endocrine disorders, 59, 60, 60, 61
energy expenditure, 52–3, 53
energy intake, 51, 51, 52
environmental factors, 61–2, 62
genetic factors, 53–4, 54
hormones, neurotransmitters, and peptides, in food intake
control, 52
molecular epidemiology, 55–6, 56–8, 58–9
multifactorial factors, obesity development, 50, 50
pregnancy, 63
psychosocial influences, 62–3
smoking, 63
body mass index (BMI), 47, 48
clinical assessment, 68–9, 70–71, 72
clinical presentation
assessment methods, 65
body composition, 65–6
body-fat estimation methods, 66
comorbidities, 67, 67, 67–8
fat distribution, 66–7
definitions and classification, 47, 47–8
economic impact and global burden, 48–50, 49
growth of obesity, 48, 49
liver disease, 195
prevention
childhood obesity, 78–9
multidimensional approach, 79, 79
relative risks (RR), 49
treatment approaches
bariatric surgery, 75–7
dietary management, 72–3
gastric pacing, 78
intragastric balloon (IGB) therapy, 77–8
lifestyle changes, 72
pharmacotherapy, 73–5
physical activity, 73
principles, 72
overweight, 48, 65 see also over-nutrition
children, 470, 471–2, 473–4
chronic kidney disease, 247
identification and management, algorithms, 70–71
Owen’s equation, energy requirements, 141
oxidative stress, osteoporosis, 345
paediatric nutrition
acutely ill child, diarrhoeal disease
dehydration, degree, 464
feeding, 465
fluid replacement, 464, 464–5, 465
management, 463–4
persistent diarrhoea, 465
ReSoMal and oral rehydration solutions, 465
applications of nutritional science principles, 421
chronically ill child, 465–6
exclusion diets, 466–7
growth
body composition, 430, 430–432, 430–434
distance and velocity charts, 423, 423–7, 426, 427
infancy, 426–7, 428
infant, child, and pubertal (ICP) phases, 426, 427
nine-centile growth chart, 429
optimal growth, international standards, 426
physiological deviations from growth references, 426–7, 430
pubertal growth spurt, timing, 427
paediatric nutrition (cont’d)
puberty, 427, 429, 430
references and standards, 422–3
UK-WHO 0–4 years growth chart, 423, 423–7
impact of development
gastrointestinal maturation, 434
metabolic maturation, 435–6
neurological maturation, 433, 433
renal maturation, 434–6, 436
inborn errors of metabolism
amino and organic acid disorders, 467
carbohydrate metabolism, 468
lipid metabolism, 468
phenylketonuria, 469, 469–70
infant feeding
breast-feeding, 437–9
complementary feeding, 439–41
dietary supplements, 441–2
effect of feeding on growth, 441, 441
formula feeding, 439, 440
long-term relevance, 421–2, 422
nutritional support for sick child
enteral feed, types, 459–60
enteral nutrition, routes of access, 459
glucose, 461–2
lipid, 462
nitrogen, 462
parenteral feeding, 460–461, 461
principles, 457, 458, 459
tube feeds, administration, 460
vitamins and trace minerals, 462–3
weight loss and catch-up, 458
overweight in children
causes, 473
complications, 473
definition, 470, 471–2, 473
prevention, 474
treatment, 473–4
preschool children
behavioural eating problems, 443–4
dietary problems, 443
schoolchildren and adolescents, 444–6
under-nutrition in children, 446–57
vulnerability
demands, 420–421
imbalance of supply and demand, 421
supply, 421
palliative nutrition, 409
pancreas
diabetes mellitus see diabetes mellitus
pancreatitis see pancreatitis
pancreatic ascites, 228
pancreatic enzyme replacement therapy (PERT), 490, 494–5
effectiveness, factors influencing, 496
gastric emptying pattern, 496
recommendations, 496
pancreatic fistulas, 228
pancreatic insufficiency (PI), cystic fibrosis
coefficient of fat absorption (CFA), 489
fat malabsorption, 488–9
immunoreactive trypsinogen (IRT), 489
pancreatic sufficient (PS), 488
pancreatitis
acute
bacterial translocation, 221
metabolic consequences, 222
pathogenesis, 220–221
artificial nutrition
early nutritional support, 225
energy requirements, 225–6
enteral nutrition, 224–5
enteral route, jejunal/gastric, 225
micronutrients, 226
parenteral nutrition, 223, 224
pharmaceuticals and probiotics, 226
practical guidelines, 226–7
protein requirements, 226
chronic
artificial nutrition, 227–8
complications, nutrition management, 228
nutritional status and deficiencies, 227
mild and severe, 220
severity scores, 221–2
Glasgow score, 222
Ranson score, 222
parathyroid hormone (PTH), bone disease, 343–4
parenteral nutrition, 8–9, 9
cancer patients, vs. enteral tube feeding, 407, 408
catheter access, 154
catheter-related sepsis, 155
cirrhosis, 204, 205
haematopoietic stem-cell transplantation, 262–3
HIV-associated wasting, 371
and immune function, 286, 296
indications, 153
intravenous, 250
monitoring and complications, 154–5
pancreatitis, 223, 224
parameters, 156
perioperative care, 356
sick child, routes of access, 459, 461
solutions, 154
supplemental, cancer patients, 411–12
vitamin and trace-elements, 154, 155
peanut allergies, 134–5
pentoxifylline, cancer patients, 418
percutaneous endoscopic gastrostomy (PEG)
enteral feeding, 146
and nasogastric feeding, stroke, 167
percutaneous endoscopic jejunostomy (PEJ), enteral feeding, 146
perioperative care, nutritional support
adverse effects, elective surgery patients, 357–8
balancing fluids, 359
combined treatment programme, metabolic effects, 360
drains, tubes, and catheters, 360
enhanced recovery after surgery, 358, 358–9
glucose control, critically ill, 356–7
malnourished/complicated surgical patient
postoperative feeding, 356, 357
preoperative, 356
minimally invasive surgical techniques, 359–60
uncomplicated patient
bowel cleansing, 355
postoperative management, 355–6
preoperative management, 355
small-to medium-size surgery, 355
peripheral blood-progenitor cell transplant (PBPC), 260
peripheral vascular disease and diet, 321
persistent vegetative states (PVS), nutritional support, 170–71
phenylalanine hydroxylase, 6
phenylketonuria (PKU), 6, 469, 469–70
phosphate, chronic kidney disease, 237, 247
phosphorus, mineral-ion homeostasis, 331–2
physical-activity levels (PALs), under-nutrition, 91, 91
plant sterols and stanols, coronary heart disease, 316
polyunsaturated fatty acids (PUFAs) and coronary heart disease, 307, 307
immune and inflammatory systems, 286, 294, 295
post-pyloric feeding, 147
potassium, 32
body secretions, 4, 4
chronic kidney disease, 248
potential renal solute load (PRSL), 435, 436
pregnancy and diabetes, 216
preterm infants, mineral-ion homeostasis, 342–3
proinflammatory cytokines adverse effects, body composition, 283
body temperature and appetite, alteration, 279
fats influence, 292–3
liver protein synthesis, changes, 280, 280
metabolic changes, 279
physiological and metabolic effects, 278
production, physiological and metabolic acids consequences, 279
protein and fat metabolism, changes, 279
trace-element and vitamin metabolism, changes, 279–80
protein and amino acid metabolism, liver disease acute liver failure, 199
cirrhosis, 199, 199
surgery and transplantation, 199–200, 200
cancer patients, 413
effect of disease, 4–5, 5
intake, chronic kidney disease, 236–7
metabolism acute kidney injury, 234
cancer patients, 393–4
HIV infection, 368–9
proinflammatory cytokines, 279
trauma, 353
under-nutrition, 84–6, 85
protein–energy malnutrition (PEM) chronic kidney disease, 239–42, 249
cytokines, 284
inflammatory bowel disease, 185
malaria, 379
nutritional assessment, 21, 22
clinical examination, 22
clinical history, 21
protein energy wasting (PEW), 242
protein-mobilising factors (PMFs), 399
puberty, growth, 427, 429, 430
pyridoxine, chronic kidney disease, 248
quality of life and malnutrition, cancer patients, 403
quantitative computed tomography (QCT), 338
radiotherapy, cancer cachexia, 399–400, 400
Ranson score, pancreatitis, 222
reactive oxygen species (ROS), Wnt/β-catenin, 348
recommended dietary intake (RDI), calcium, 331
rectal feeding, 10
refeeding syndrome, 11, 93, 115–16, 157
anorexia, 504–6, 505, 506
reference nutrient intake (RNI), 3
renal function, salt and water overload, 40
renal maturation, paediatric nutrition, 434–6, 436
renal replacement therapy (RRT) patients dietary prescription, 246, 246
guidelines, 241–2
nutritional support, 249, 249–50
renal solute load (RSL), 434–5
renin–angiotensin–aldosterone system (RAAS), 31, 34
resins, coronary heart disease, 311
ReSoMal, 453, 465
resting energy expenditure (REE) cancer patients, 390, 391
Harris–Benedict equation, 104
HIV infection, 368
liver disease, 197
retinopathy, 217–18
reverse cholesterol transport, 310–311
rickets, 455, 455
chronic renal disease, 341
definition, 338
fat malabsorption, 340–341
liver disease, 305
sarcopenia, 81
saturated fat consumption and coronary heart disease epidemiology, 303–5, 304, 305
experimental evidence, 305
reduction, effect, 305–6
Schofield equations for basal metabolic rate, 505
schoolchildren and adolescents, 444–6
secondary hyperparathyroidism, 243, 341
selenium cardiovascular disease, 324
cystic fibrosis, 499
senile osteoporosis pathophysiology, 347
preventative strategies, 347
serum albumin concentration, inflammatory response, 280
severe acute malnutrition (SAM), children, 89–90
short-bowel syndrome, 178, 188
sibutramine, 74
single-nucleotide polymorphisms (SNPs), 281, 282
sirtuin, 99
skeleton age-appropriate biochemical reference ranges
alkaline phosphatase, 336
insulin-like growth factor 1, 336
osteocalcin, 336, 336
phosphate, 336
anorexia nervosa, 346
skeleton (cont’d)
  bone metabolism, 327–9
  corticosteroid-induced bone disease, 343–4
  diagnostic imaging assessment
    bone age, 337
    bone ultrasound, 338
    DEXA bone density, 337–8
    QCT, 338
  endochondrial bone formation, cellular interactions, 328
  feed-forward regulation loop links insulin, bone resorption, and osteocalcin, 336
  mineral-ion homeostasis
    calcium, 329, 330
    phosphorus, 331–2
    preterm infants, 342–3
  osteoporosis with chronic disease, 345–6
  peak bone mass, factors, 329
  pharmaceutical agents, bone disease
    hypoparathyroidism and genetic forms, 337
    osteoporosis, 337
    vitamin D-deficient rickets and osteomalacia, 336–7
  post-transplant bone disease, 344–5
  reactive oxygen species (ROS), Wnt/b-catenin, 348
  rickets/osteomalacia (vitamin D deficiency)
    chronic renal disease, 341
    fat malabsorption, 340–41
    genetic disorders, 341
    institutionalised and frail elderly, 340
    risk factors, 338–9
    severe dietary calcium deficiency, 341
    senile osteoporosis, 346–7
  vitamin D metabolism, 330, 333–5, 334, 335
  sodium, 32
    blood pressure regulation, 319–20
    body secretions, 4
    cardiovascular disease, 323
    chronic kidney disease, 248
    and water metabolism implications, nutrition therapy
      congestive heart failure and cirrhosis, 44
      diarrohaeal illness, 44
    stroke, dysphagia, and elderly, 44–5
    soy, allergy, 131, 134
    soy protein, coronary heart disease, 315
    Starling’s equation, fluid movements across capillary wall, 28
  starvation
    body water compartments and electrolytes, 36–7, 39
    and low weight, eating disorders
      medical complications, 113–14
      nutritional problems, 115–17
    metabolic response, 36
  statins, coronary heart disease, 312–13
  stavudine, 373
  steroid-induced osteoporosis, prevention and treatment, 344
  stroke
    artificial nutritional support, ethical principles, 167–8
    definition, 167
    and diet, 321
    PEG and nasogastic feeding, 167
  Subjective Global Assessment (SGA), nutritional screening, 17, 18
  sucrose, 216
  surgery, nutritional support see perioperative care, nutritional support
  systemic inflammatory response syndrome (SIRS), 220, 221, 280, 281
  T cells, dietary antigen, 136
  tea, coronary heart disease, 316
  testosterone, HIV-associated wasting, 371
  thalidomide
    cancer patients, 418
    HIV-associated wasting, 372
  T helper cells, dietary antigen, 136–7
  thermogenesis, 83–4
    total energy expenditure, 52–3
    thirst regulation and water balance, 35
  thirst stimulation
    hypovolaemia, 35–6
    plasma osmolality and sodium concentration, 35
  thyrotoxicosis, case study, 506
  TNF2 allele, 281, 282
  total energy expenditure (TEE), 91
    acute disease severity effect, 5, 5
    basal metabolic rate, 52
  cancer, 390, 412
  HIV infection, 368
  physical activity, 53
    thermogenesis, 52–3
  total energy intake, 104
  total enteral nutrition (TEN), Crohn’s disease, 188–9
  total parenteral nutrition (TPN), 153, 157
  cancer patients
    nutritional status, 403–7
    randomised clinical trials, meta-analysis, 409
    surgery, nutritional support, 406–7
    immune function, 296–8
    inflammatory bowel disease, 187–8
  trace-elements
    deficiencies and manifestations, 24
    intravenous (IV) nutrition, recommended doses, 9
    metabolism changes, proinflammatory cytokines, 279–80
    parenteral nutrition, 154, 155
    trace-minerals, children
      deficiency, 457
      requirements, 462–3
    transcription-factor activation, oxidants and antioxidant effects, 284, 290, 290–291
  trans-fatty acids and coronary heart disease, 308
  trauma
    feeding, severely traumatised patient, 360–361
    stress response
      ebb and flow phases, 351
      hypermetabolism, 351–3
      insulin resistance, 353–4, 354
      protein metabolism, 353
      sequence of events, 351, 351
    traveller’s diarrhoea, 380
    triacylglycerol (TAG), 309, 310, 314
    tropical enteropathy and tropical sprue
      concept and epidemiology, 182
      pathogenesis, 183
      pathology and clinical relevance, 182–3
      treatment, 183
    tube feeding, 119
  tuberculosis
    body composition, 377
    causative agent and transmission, 376
    clinical presentation, treatment, and course, 376
    epidemiology and importance, 375–6
    and malnutrition, 377
    micronutrient supplementation, 378
nutritional and metabolic effects, 376–7
nutritional therapy for wasting, 377–8
pharmacological treatments for wasting, 378
tumour growth, nutritional support effects, 414–15
tumour necrosis factor alpha (TNFα), 396–7
type 1 diabetes, 209, 211
type 2 diabetes, 102–3, 209, 211
UK-WHO growth reference, 429
ulcerative colitis, 183 see also inflammatory bowel disease (IBD)
under-nutrition
assessment, 90
cachexia, 81, 82
cancer cachexia, 388–9
in children, 446–57
chronic under-nutrition (CED), 88
elderly, 88–9
functional consequences, 82
infection and injury, pathophysiology
energy metabolism, 86, 87
hormonal mediators, 87–8
protein metabolism, 87
weight loss, 87
inflammation, aetiology-based terminology, 82
liver disease, 194–5
nutritional supplementation, problems with, 95
chronic under-nutrition, 93–4
enteral and parenteral nutrition, 93
refeeding syndrome, 93
pathophysiology
body composition, 82
energy metabolism, 82–4, 83–4
hormonal mediators, 86
immune function, 86
protein metabolism, 84–6, 85
physical and psychosocial effects of, 2
prevention, 94
protein metabolism
injury, 87
N balance and energy intake, 85, 85
nitrogen (N) excretion, high to low protein intake, 84, 85
potassium and phosphorus, 86
protein turnover, 85
sarcopenia, 81
severe acute malnutrition (SAM), in children, 89–90
subclassification, 81
treatment
Harris–Benedict equation, energy requirement
calculation, 90
micronutrient deficiencies, clinical manifestations, 92, 92
nonessential amino acids, 91–2, 92
physical-activity levels (PALs), 91, 91
protein requirements, 91
uraemia, protein-energy malnutrition, 240
urodilatin, 34
vasodilatory effects of insulin, 103
vasopressin, 33, 34
veno-occlusive disease (VOD) of liver, 261–2
very low-density lipoproteins (VLDLs), 309
vitamin A
deficiency
children, 455–6
cytokines, 284–5
malaria, 379
vitamin B deficiency, children, 456–7
vitamin B12, immune and inflammatory systems, 289–90
vitamin C
chronic kidney disease, 248
deficiency, children, 457
intake, immune and inflammatory systems, 288–9
vitamin D
deficiency
children, 454–5, 455
osteomalacia see osteomalacia
rickets see rickets
metabolism, in liver and kidney, 6–7, 7
metabolism, skeleton, 330
age-related recommended daily intake (RDI), 334
dietary sources, 335
hydroxylation, 333
skin production, 333–5
supplementation
infancy, 442
tuberculosis, 378
vitamin E
deficiency, children, 457
immune and inflammatory systems, 287–8
vitamin K, in infancy, 441–2
vitamins
acute kidney injury, 235
and cardiovascular disease
vitamin A, 322
vitamin B1 (thiamine), 323
vitamin B6, B12, and folate, 323
vitamin C, 323
vitamin D, 323
vitamin E, 323
chronic kidney disease, 248–9
deficiencies
cancer patients, 394–5
and manifestations, 23
eating disorders, 116
intravenous (IV) nutrition, recommended doses, 9
parenteral nutrition, 154, 155
supplementation, cystic fibrosis
multivitamins, 498
recommendations, 497
vitamin A and beta-carotene, 497
vitamin D, 498
vitamin E, 498
vitamin K, 498
water-soluble vitamins, 498
wasting
HIV-associated wasting see human immunodeficiency virus (HIV) infection,
HIV-associated wasting syndrome
definition, 365
epidemiology, 365
tuberculosis, 376–8
water administration, cancer patients, 413–14
water and electrolytes
body electrolyte content and concentration, 31–2, 32
body water compartments
capillary permeability and albumin flux, 30
electrolyte concentrations, 28
and electrolytes, in starvation and injury, 36–7, 39
hydrostatic and oncotic pressure gradients, effect, 29
water and electrolytes (cont’d)
regulation, 32–6
Starling’s equation, 28
fluid therapy
assessment, 41–2
gastrointestinal secretions, electrolyte content, 43
maintenance fluid, 43
resuscitation, 42–3
treatment, 42
goal-directed fluid therapy, 43
kidney and gastrointestinal tract, fluid flux, 30–31, 31
metabolic response
injury, 36
starvation, 36
salt and water overload
crystalloids, 38, 39
gastrointestinal function, 40
low serum albumin concentrations, 40–41, 41
renal function, 40
saline infusion, oedema, 40
wheat intolerance, 134
World Health Organization (WHO)
classification, of overweight and obesity, 48
diarrhoea, management, 463–4, 464
UNICEF mixture, oral rehydration solutions, 382–3
weight-for-height, 452
zinc
cardiovascular disease, 324
cystic fibrosis, 499
deficiency, children, 456
eating disorders, 117
malaria, 379